Simon-Kucher Appoints Seven New Partners in the Life Sciences Sector and Expands Thought Leadership

The Healthcare and Life Sciences division at consultancy Simon-Kucher & Partners continues to grow: By announcing seven new partners, the international team increases its presence in several healthcare subsectors around the globe.

| Press Release
Meet The Rebel Financial Advisor Helping Investors Save On Taxes

The percentage guys are not doomed to extinction.

| Press Release
New Partners at Simon-Kucher: Tackling New Challenges in Life Sciences

Even though 2020 was a challenging year, our company continues to grow – and so does our leadership team.

| People & Stories
price control measures
PMPRB Strips Off Stringiest Policies Initially Proposed

The new PMPRB guidelines will go into effect in July, but only after removing some of the more stringent price control measures initially proposed.

| Blog | Healthcare & Life Sciences Pharma & Biotechnology Pricing Strategy & Revenue Management
Insurance in 2021: A tale of the ant and the grasshopper

The insurance hardening market cycle that began more than three years ago is being exacerbated by falling investment returns from the low-interest-rate environment as well as the onslaught of risks associated with the coronavirus pandemic and climate change.

| Press Release
Playing with Fire: How to Pass On Negative Interest Rates Successfully

Until recently, negative interest rates were taboo in Germany, but now, passing them on to corporate and private customers is what’s driving the banking industry.

| Blog | Financial Services Banking Wealth & Asset Management Customer, Product & Market Strategy Pricing Strategy & Revenue Management
fundraising events
Becca’s Story: Inspiring Others to Make a Big Difference

Becca Horton, Office Manager in our San Francisco and Silicon Valley locations, has strived to make a difference from day one.

| People & Stories
tender strategy
8 Dos and Don’ts of Tender Strategy and Execution in Pharma

Tenders are becoming increasingly relevant for purchasing in the healthcare sector, particularly for established products at the mature stage of the product lifecycle.

| Blog | Healthcare & Life Sciences Pharma & Biotechnology Commercial Strategy & Pricing Consulting
brochure cover
Successfully Commercializing Orphan and Ultra-Orphan Drugs

Orphan and ultra-orphan diseases are the less traveled but increasingly promising path for the biopharmaceutical industry.

| Perspective | Whitepaper | Healthcare & Life Sciences
China NRDL Outlook
Embracing the Change: 2020 China NRDL Outlook

China’s 2020 NRDL (National Reimbursement Drug List) process has been unfolding since July this year with a number of new changes and interesting twists.

| Blog | Healthcare & Life Sciences Pharma & Biotechnology Commercial Strategy & Pricing Consulting
Language
Search